About givosiran
Small interfering RNA therapy
Used for
- Prevention of recurrent acute hepatic porphyria attacks in adults and adolescents aged 12 years or older.
Usual adult dose
2.5 mg/kg by subcutaneous injection once monthly.
Usual dose in children
For ages 12 years and older: 2.5 mg/kg by subcutaneous injection once monthly.
Common side effects
- Nausea
- Injection-site reactions
- Fatigue
- Increased liver enzymes or kidney function markers
Important warnings
- Monitor liver enzymes before treatment and during the first months.
- Monitor kidney function and homocysteine levels during treatment.
- Serious allergic reactions can occur.
- May increase blood homocysteine levels.
Pregnancy
Human pregnancy information is limited; potential risks are uncertain. Discuss treatment risks with a clinician.
Breastfeeding
It is unknown whether givosiran passes into breast milk; information on effects is limited.
Interactions
- May increase exposure to certain medicines, including warfarin and some statins; medication monitoring may be needed.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.